AcuityMD Secures $80M for Agentic AI in MedTech Sales
AcuityMD, a MedTech data platform, has secured $80 million in Series C funding led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. This round brings the company's total funding to over $160 million and values it at $955 million. The capital will accelerate the rollout of AcuityAI, an agentic AI tool designed to optimize commercial sales by providing actionable insights for territory prioritization and market trends. With over 400 MedTech companies, including 16 of the top 20 global organizations, using its platform to identify over $34 billion in pipeline, AcuityMD aims to expand beyond sales into the full product lifecycle, supporting research, development, and launch phases for next-generation medical innovations.
Funding and Market Traction
The $80 million Series C funding round, led by StepStone Group, underscores investor confidence in AcuityMD's growth trajectory. The company has now raised over $160 million, achieving a valuation of $955 million. Its platform is widely adopted, serving over 400 MedTech companies, including 16 of the top 20 global organizations. To date, AcuityMD has helped customers identify more than $34 billion in pipeline, demonstrating significant impact in the high-pressure MedTech sales environment.
Agentic AI Rollout and Technology
AcuityMD is using the fresh capital to accelerate AcuityAI, currently in open beta. This agentic AI leverages a proprietary MedTech ontology that aggregates fragmented data from claims databases, FDA filings, and government records into a continuously enriched knowledge graph. The tool maps entities like physicians and facilities, tracks market dynamics such as procedures and reimbursement trends, and integrates internal data like contracting info and CRM activity. It allows sales reps and leaders to query complex business questions and receive immediate, actionable business plans, reducing research time and improving engagement with physicians.
Industry Impact and Future Vision
AcuityMD addresses challenges in the MedTech landscape, including hospital consolidation, regulatory changes, and reimbursement updates. By providing real-time insights, the platform helps companies navigate shifting competitive dynamics. Testimonials, such as from Mark Edwards of Kuros Biosciences, highlight how AcuityAI surfaces insights that previously took hours, enabling quick business planning. Beyond commercial execution, the funding will support three growth pillars: developing specialized AI agents for sales, marketing, and leadership; deepening the ontology data model; and expanding platform support across the full product lifecycle, from pre-commercial stages to adoption.
